- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about ESALY
Recent news which mentions ESALY
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
From Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
From Benzinga
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
From InvestorPlace
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
December 18, 2022
From Motley Fool
Eating these simple foods may slow Alzheimer’s by a third
December 16, 2022
From MarketWatch
Why 2023 Could Be a Big Year for Biogen
December 07, 2022
From Motley Fool
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
December 05, 2022
From InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
From Motley Fool
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
From Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
From Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
From Benzinga
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
From Motley Fool
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
From Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
From Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
From Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
October 29, 2022
From Motley Fool
Is Biogen a Buy After It Boosted Guidance?
October 26, 2022
From Motley Fool
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
October 24, 2022
From Benzinga
3 Alzheimer's Therapy Stocks to Invest in
October 21, 2022
From Motley Fool
Does Biogen's Recent Win Make It a Must-Buy Stock?
October 12, 2022
From Motley Fool
4 Biotech Stocks With Huge Incoming Catalysts
October 12, 2022
From Motley Fool
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
From Benzinga
Hey Biogen Investors, Don’t Chase BIIB Stock!
October 05, 2022
From InvestorPlace
2 Signals to Watch Before Buying SAVA Stock
October 05, 2022
From InvestorPlace
Is Biogen a Smart Biotech Stock to Buy Right Now?
September 29, 2022
From Motley Fool
Why Moderna Stock Lagged the Market Today
September 28, 2022
From Motley Fool
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
From Benzinga
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
September 28, 2022
From InvestorPlace
Why Is Acumen (ABOS) Stock Up 95% Today?
September 28, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.